Visterra raised a $30m Series B round from new and existing venture capital investors to fund clinical development of the company's pipeline of novel monoclonal antibodies to prevent and treat infectious diseases.
Cambridge, Massachusetts-based Visterra will use the new cash to complete a Phase I clinical trial and conduct a Phase II...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
